주식/증권
📈 긍정적
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
요약
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.